Literature DB >> 27847273

Development of 1-aryl-3-furanyl/thienyl-imidazopyridine templates for inhibitors against hypoxia inducible factor (HIF)-1 transcriptional activity.

Shinichiro Fuse1, Toshiaki Ohuchi1, Yasunobu Asawa1, Shinichi Sato1, Hiroyuki Nakamura2.   

Abstract

1,3-Disubstituted-imidazopyridines were designed for developing inhibitors against HIF-1 transcriptional activity. Designed compounds were rapidly synthesized from a key aromatic scaffold via microwave-assisted Suzuki-Miyaura coupling/CH direct arylation sequence. Evaluation of ability to inhibit the hypoxia induced transcriptional activity of HIF-1 revealed that the compound 2i and 3a retained the same level of the inhibitory activity comparing with that of known inhibitor, YC-1 (1). Identified, readily accessible 1-aryl-3-furanyl/thienyl-imidazopyridine templates should be useful for future drug development. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CH direct arylation; Hypoxia inducible factor (HIF)-1; Imidazopyridine; Microwave

Mesh:

Substances:

Year:  2016        PMID: 27847273     DOI: 10.1016/j.bmcl.2016.11.009

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Synthesis of imidazo[1,5-a]pyridines via cyclocondensation of 2-(aminomethyl)pyridines with electrophilically activated nitroalkanes.

Authors:  Dmitrii A Aksenov; Nikolai A Arutiunov; Vladimir V Maliuga; Alexander V Aksenov; Michael Rubin
Journal:  Beilstein J Org Chem       Date:  2020-11-26       Impact factor: 2.883

Review 2.  Synthetic strategy and structure-activity relationship (SAR) studies of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1, Lificiguat): a review.

Authors:  Ko-Hua Yu; Hsin-Yi Hung
Journal:  RSC Adv       Date:  2021-12-20       Impact factor: 3.361

3.  Synthesis of 3-aryl-1-phosphinoimidazo[1,5-a]pyridine ligands for use in Suzuki-Miyaura cross-coupling reactions.

Authors:  Ryan Q Tran; Long P Dinh; Seth A Jacoby; Nekoda W Harris; William A Swann; Savannah N Williamson; Rebecca Y Semsey; Larry Yet
Journal:  RSC Adv       Date:  2021-08-23       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.